SARASOTA, Fla., March 14, 2017 -- Roper Technologies, Inc. (NYSE:ROP) announced that its Board of Directors has approved a dividend of $0.35 per share payable on April 21, 2017 to stockholders of record on April 7, 2017.
About Roper Technologies
Roper Technologies is a constituent of the S&P 500, Fortune 1000, and the Russell 1000 indices. Roper designs and develops software (both software-as-a-service and licensed), and engineered products and solutions for healthcare, transportation, food, energy, water, education and other niche markets worldwide. Additional information about Roper is available on the Company’s website at www.ropertech.com.
Contact Information: Investor Relations +1 (941) 556-2601 [email protected]


Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



